An independent data monitoring committee completed its review of Amarin Corp.'s (Nasdaq: AMRN) REDUCE-IT cardiovascular outcomes study and recommended no modifications. The stock price lost 22 cents to close at $2.95.
Independent committee ends review of Amarin
September 12, 2016 at 19:20 PM EDT
